RCT 150 outpatients in Iran comparing N-acetylcysteine and bromhexine, showing lower hospitalization and faster recovery with bromhexine, without statistical significance. Baseline information per group is not provided, and Figure 1 appears to have the two groups switched and an incorrect value for the not hospitalized total in one group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days.
Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
This study is excluded in the after exclusion results of meta
analysis:
results unclear due to errors in the preprint, baseline group details not provided.
|
risk of hospitalization, 45.5% lower, RR 0.55, p = 0.30, treatment 6 of 75 (8.0%), control 11 of 75 (14.7%), NNT 15.
|
|
recovery time, 14.9% lower, relative time 0.85, p = 0.09, treatment 75, control 75.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, this trial compares with another treatment - results may be better when compared to placebo, trial
IRCT20220302054167N1.
Contact:
anahitaeslami1995@gmail.com.
Abstract: Evaluation of the recovery rate and prevention of
hospitalization among covid-19 outpatients: a
randomized clinical trial comparing Nacetylcysteine with Bromhexine
Anahita Eslami Ghayour ( anahitaeslami1995@gmail.com )
Hamedan University of medical science
Sasan Nazari
Hamedan University of medical science
Fariba Keramat
Hamedan University of medical science
Fatemeh Shahbazi
Hamedan University of medical science
Research Article
Keywords: COVID-19, N-acetylcysteine, Bromhexine, Infection diseases
Posted Date: January 3rd, 2023
DOI: https://doi.org/10.21203/rs.3.rs-2309373/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Page 1/12
Abstract
Objectives: Due to the referral of COVID-19 patients to outpatient centers in the early stages, the aim of
the present study is to compare the effect of N-acetylcysteine and Bromhexine on the recovery rate and
prevention of hospitalization in outpatients with COVID-19
Methodology: This study was conducted from April 2022 to September 2022. First, PCR-confirmed
COVID-19 patients were divided into two groups, one of these groups received N-acetylcysteine while the
other received bromhexine. The patients were followed up on the seventh and fourteenth days of the
disease in terms of the duration of changes in oxygen saturation and recovery. The hospitalization and
death of the patients were also evaluated after one month.
Results: Out of 150 studied patients, oxygen saturation was increased by 1.33% in the third visit of the
patients who received N-acetylcysteine compared to their first visit. This percentage was 1.19% in the
patients who received bromhexine.11.33% of the patients were admitted to the hospital and 88.6% of
them had no history of hospitalization within 14 day and their mortality rate was zero.
Conclusions: The results of this study showed that early initiation of Bromhexine can effectively reduce
the hospitalization rate and shorten the duration of hospitalization.
Clinical trial code: IRCT20220302054167N1 and ethics code: IR.UMSHA.REC.1400.957
